Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: Therapeutic implications for Alzheimer's disease and late cognitive impairment

Gerontology

Volumn 54, Issue 4, 2008, Pages 238-243

  Waugh, William H ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Ascorbic acid; Brain iron; Fenton reaction; Longevity; Uric acid

Indexed keywords

ASCORBIC ACID; HEMOGLOBIN; HYDROGEN PEROXIDE; IRON; SODIUM CHLORIDE; URIC ACID;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); EXTRACELLULAR FLUID; FENTON REACTION; PH; PHYSIOLOGY; PLASMA; PRECIPITATION; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANTIOXIDANTS; ASCORBIC ACID; COGNITION DISORDERS; HEMOGLOBINS; HYDROGEN PEROXIDE; IRON; OXIDATION-REDUCTION; PHOTOMETRY; URIC ACID;

EID: 45549085866     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122618     Document Type: Article

References (38)

1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO: Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA 1989;262:2551-2556.
2. Brookmeyer R, Gray S, Kawa C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
3. Espeland MA, Henderson VW: Preventing cognitive decline in usual aging. Arch Intern Med 2006;166:2433-2434.
4. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA: Involvement of oxidative stress in Alzheimer disease. J Neuropath Exp Neurol 2006;65:631-641.
5. Markesbery WE, Lovell MA: Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 2007;64:954-956.
6. Waugh WH: Cognitive decline therapy by iron burden reduction. Arch Intern Med 2007;167:1098.
7. Goodman L: Alzheimer's disease a clinicopathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Mental Dis 1953;117:97-130.
8. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P: A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
9. Todorich BM, Connor JR: Redox metals in Alzheimer's disease. Ann NY Acad Sci 2004;1012:171-178.
10. Halliwell B: Oxidants and the central nervous system: some fundamental questions is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand 1989;126:23-33.
11. Hershey CO, Hershey LA, Varnes A, Vibhakar SD, Lavin P, Strain WH: Cerebrospinal fluid trace element content in dementia: clinical, radiologic, and pathologic correlations. Neurology 1983;33:1350-1353.
12. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-cause aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-6862.
13. Cutler RG: Urate and ascorbate: their possible roles as antioxidants in determining longevity of mammalian species. Arch Gerontol Geriatr 1984;3:321-348.
14. Proctor P: Similar function of uric acid and ascorbate in man? Nature 1970;228:868.
15. Karlsson J: Antioxidants and Exercise. Champaign/IL, Human Kinetics, 1997, p 55.
16. Pomara N, Singh R, Deptula D, Chou JC-Y, Schwartz, LeWitt PA: Glutamate and other amino acids in Alzheimer's disease. Am J Psychiatry 1992;149:251-254.
17. Kuiper MA, Teerlink T, Visser JJ, Beergmans PL, Scheltens P, Wolters ECh: L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 2000;107:183-189.
18. Gutteridge JMC: Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. FEBS Lett 1986;201:291-295.
19. Waugh WH: Simplified method to assay total plasma peroxidase activity and ferriheme products in sickle cell anemia, with initial results in assessing clinical severity in a trial with citrulline therapy. J Pediatr Hematol Oncol 2003;25:831-834.
20. Varma SD, Devamanoharan PS: Hydrogen peroxide in human blood. Free Radic Res Commun 1991;14:125-131.
21. 2) plasma level and malondialdehyde serum concentration. Int J Cardiol 1996;56:137-143.
22. Pauling L: Are recommended daily allowances for vitamin C adequate? Proc Natl Acad Sci USA 1974;71:4442-4446.
23. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowski H: Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001;7:313-319.
24. Gutteridge JMC, Rowley DA, Halliwell B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Biochem J 1981;199:263-265.
25. Mikkelson WM, Dodge HJ, Valkenburg, H: The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia. Am J Med 1965;39:242-251.
26. Maesaka JK, Wolf-Klein G, Piccione JM, Ma CM: Hypouricemia, abnormal renal tubular transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc 1993;41:501-506.
27. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003;24:915-919.
28. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF: Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer's disease. Arch Neurol 2002;59:794-798.
29. Tallaksen CM, Bøhmer T, Bell H: Concentrations of the water-soluble vitamins thiamin, ascorbic acid, and folic acid in serum and cerebrospinal fluid of healthy individuals. Am J Clin Nutr 1992;56:559-564.
30. Tohgi H, Abe T, Takahashi S, Kikuchi T: The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer's-type dementia, and Parkinson's disease. J Neural Transm 1993;6:119-126.
31. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JCM, Breteler MMB: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-3229.
32. Clifford AJ, Riumallo JA, Young VR, Scrimshaw NS: Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. J Nutr 1976;106:428-450.
33. Wesson LG: Physiology of the Human Kidney. New York, Grune & Stratton, 1969, pp 182-186, 221.
34. Wolfson WQ, Levine R, Tinsley M, The transport and excretion of uric acid in man I. True uric acid in normal cerebrospinal fluid, in plasma, and in ultrafiltrates of plasma. J Clin Invest 1947;26:991-994.
35. Quinn J, Suh J, Moore MM, Kaye J, Frei B: Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain. J Alzheimer's Dis 2003;5:309-313.
36. Maples KR, Mason RP: Free radical metabolite of uric acid. J Biol Chem 1988;263:1709-1712.
37. Simic MG, Jovanovic SV: Antioxidation mechanisms of uric acid. J Am Chem Soc 1989;111:5778-5782.
38. Rodwell VW: Nucleotides; in Murray RK et al. (eds): Harper's Biochemistry, ed 24. Stamford, Appleton & Lange, 1996, p 360.